Island Pharmaceuticals Limited ILA.AX Stock
Island Pharmaceuticals Limited Price Chart
Island Pharmaceuticals Limited ILA.AX Financial and Trading Overview
| Island Pharmaceuticals Limited stock price | 0.06 AUD |
| Previous Close | 0.13 AUD |
| Open | 0.13 AUD |
| Bid | 0.1 AUD x N/A |
| Ask | 0.13 AUD x N/A |
| Day's Range | 0.13 - 0.13 AUD |
| 52 Week Range | 0.07 - 0.22 AUD |
| Volume | 43.85K AUD |
| Avg. Volume | 22.74K AUD |
| Market Cap | 10.56M AUD |
| Beta (5Y Monthly) | 0.178768 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ILA.AX Valuation Measures
| Enterprise Value | 7.24M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2317.373 |
| Price/Book (mrq) | 3.6111112 |
| Enterprise Value/Revenue | 1588.059 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Island Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 0.178768 |
| 52-Week Change | 8.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.22 AUD |
| 52 Week Low | 0.07 AUD |
| 50-Day Moving Average | 0.1 AUD |
| 200-Day Moving Average | 0.14 AUD |
ILA.AX Share Statistics
| Avg. Volume (3 month) | 22.74K AUD |
| Avg. Daily Volume (10-Days) | 2.66K AUD |
| Shares Outstanding | 81.27M |
| Float | 24.45M |
| Short Ratio | N/A |
| % Held by Insiders | 73.20% |
| % Held by Institutions | 4.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -77023.64% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.23% |
| Return on Equity (ttm) | -77.46% |
Income Statement
| Revenue (ttm) | 4.56K AUD |
| Revenue Per Share (ttm) | 0 AUD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -3371648 AUD |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.43M AUD |
| Total Cash Per Share (mrq) | 0.04 AUD |
| Total Debt (mrq) | 108.12K AUD |
| Total Debt/Equity (mrq) | 3.72 AUD |
| Current Ratio (mrq) | 5.286 |
| Book Value Per Share (mrq) | 0.036 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2482967 AUD |
| Levered Free Cash Flow (ttm) | -1334180 AUD |
Profile of Island Pharmaceuticals Limited
| Country | Australia |
| State | VIC |
| City | Camberwell |
| Address | 697 Burke Road |
| ZIP | 3124 |
| Phone | 61 3 7036 7675 |
| Website | https://www.islandpharmaceuticals.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Q&A For Island Pharmaceuticals Limited Stock
What is a current ILA.AX stock price?
Island Pharmaceuticals Limited ILA.AX stock price today per share is 0.06 AUD.
How to purchase Island Pharmaceuticals Limited stock?
You can buy ILA.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Island Pharmaceuticals Limited?
The stock symbol or ticker of Island Pharmaceuticals Limited is ILA.AX.
Which industry does the Island Pharmaceuticals Limited company belong to?
The Island Pharmaceuticals Limited industry is Biotechnology.
How many shares does Island Pharmaceuticals Limited have in circulation?
The max supply of Island Pharmaceuticals Limited shares is 113.78M.
What is Island Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Island Pharmaceuticals Limited PE Ratio is now.
What was Island Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Island Pharmaceuticals Limited EPS is -0.03 AUD over the trailing 12 months.
Which sector does the Island Pharmaceuticals Limited company belong to?
The Island Pharmaceuticals Limited sector is Healthcare.